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The HIV-1 envelope glycoprotein trimer is covered by
anarrayofN-linkedglycans that shield it from immune
surveillance. The high density of glycans on the trimer
surface imposes steric constraints limiting the actions
of glycan-processing enzymes, so that multiple un-
der-processed structures remain on specific areas.
These oligomannose glycans are recognized by
broadly neutralizing antibodies (bNAbs) that are not
thwarted by the glycan shield but, paradoxically,
target it. Our site-specific glycosylation analysis of a
soluble, recombinant trimer (BG505 SOSIP.664)
maps the extremes of simplicity and diversity of
glycan processing at individual sites and reveals a
mosaic of dense clusters of oligomannose glycans
on the outer domain. Although individual sites usually
minimally affect the global integrity of the glycan
shield,we identifyexamplesofhowdeletingsomegly-
canscansubtly influenceneutralizationbybNAbs that
bind at distant sites. The network of bNAb-targeted
glycans should be preserved on vaccine antigens.
INTRODUCTION
The trimeric HIV type 1 (HIV-1) envelope glycoprotein (Env) is the
sole target for broadly neutralizing antibodies (bNAbs) producedCellby the immune system during infection and is, therefore, a focus
of vaccine design. In numerous studies, bNAbs provide passive
protection from viral challenge to non-human primates (Hessell
et al., 2010; Mascola et al., 2000; Moldt et al., 2012). Many of
these bNAbs recognize epitopes that are wholly or partially
composed of glycan structures (Blattner et al., 2014; Calarese
et al., 2003; Falkowska et al., 2014; Garces et al., 2014;
Huang et al., 2014; Kong et al., 2013; McLellan et al., 2011; Mou-
quet et al., 2012; Pancera et al., 2013; Pejchal et al., 2011; Scan-
lan et al., 2002; Scharf et al., 2014;Walker et al., 2011). HIV-1 Env
is among themost heavily glycosylated proteins known, with gly-
cans making up 50% of its total mass (Lasky et al., 1986).
These abundant glycans have long been considered to shield
the trimer from immune surveillance by occluding relatively
conserved protein surfaces (Wei et al., 2003); while this concept
remains valid, it is also now evident that the glycan shield itself
can be a target for bNAbs. Defining the detailed composition
of the glycan shield will increase our understanding of bNAb epi-
topes and how HIV-1 is neutralized and, thus, help the rational
design of Env-based vaccine immunogens.
TheEnv trimer is composedof threegp120and threegp41 sub-
units. Analyses of monomeric gp120 proteins have revealed the
presence of under-processedN-glycans that remain in oligoman-
nose form (Man5-9GlcNAc2) because steric constraints impede
the actions of the endoplasmic reticulum (ER) andGolgia-manno-
sidases (Bonomelli et al., 2011;Doores et al., 2010;Goetal., 2013;
Leonard et al., 1990; Zhu et al., 2000). These oligomannose-type
glycans are mainly localized to a highly conserved area of the
gp120 outer domain, the so-called ‘‘intrinsic mannose patch,’’Reports 14, 2695–2706, March 22, 2016 ª2016 The Authors 2695
that presents numerous bNAb epitopes (Calarese et al., 2003;
Doores, 2015; Doores et al., 2015; Kong et al., 2013; Pritchard
et al., 2015c; Scanlan et al., 2002; Walker et al., 2009, 2011).
Because these studies were performed using recombinant
gp120monomers, it was uncertain at the time to what extent their
glycan content mimicked the native, trimeric structure on HIV-1
virions (Coutu and Finzi, 2015; Klasse et al., 2013; Kovacs et al.,
2014; Ringe et al., 2013, 2015). Virion-derived trimers are hard
to obtain in sufficient quantities for detailed characterizations,
but oligomannose-rich regions are known to be present on both
Envs extracted from HIV-1 virions (Bonomelli et al., 2011; Doores
et al., 2010; Pritchard et al., 2015a) andmembrane-associated re-
combinant Env (Go et al., 2015). Nonetheless, major knowledge
gaps remained to be filled.
The soluble, recombinant BG505 SOSIP.664 trimer is the pro-
totype of a class of native-like, Env-mimetic immunogens that is
now being pursued in various vaccine-development programs
(Sanders et al., 2013, 2015). On the BG505 SOSIP.664 trimers,
the glycosylation profile of the gp120 subunits is dominated by
large, oligomannose-type structures of the Man8-9GlcNAc2
type, while more complex-type structures are found on gp41
(Pritchard et al., 2015d). The native-like quaternary structure of
the SOSIP.664 trimer had a major influence on its oligoman-
nose-rich glycosylation profile; simpler (gp120 monomer) or
non-native (uncleaved gp140) Env proteins carry a much higher
content of processed glycans (Pritchard et al., 2015d; Ringe
et al., 2015). These findings led to the concept of the ‘‘trimer-
associated mannose patch’’ (TAMP) (Crispin and Doores, 2015).
Here, a quantitative, site-specific N-glycosylation analysis
reveals the fine structures of the glycan shield of the BG505
SOSIP.664 trimer. Our results confirm the remarkable overall
dominance of oligomannose-type glycans and reveal a mosaic
of glycanmicroclusters bearing under-processed glycans, espe-
cially in areas covering the gp120 outer domain and at the trimer
interfaces. At the trimer apex, there is a microcluster of glycans
of mixed processing states, with both under-processed and
complex structures present. In contrast, highly variable, but
also highly processed, complex glycans occupy the sites pre-
sent on gp41 and on the most proximal gp120 regions at the
trimer base. Deleting specific potential N-glycosylation sites
(PNGSs) does not markedly affect the overall glycosylation pro-
file of the BG505 SOSIP.664 trimer but can directly or indirectly
influence the neutralization sensitivity of HIV-1 BG505 Env-pseu-
dotyped viruses.
RESULTS AND DISCUSSION
A Glycan Library from BG505 SOSIP.664 Trimers
The design and structure of the native-like BG505 SOSIP.664
trimer have been described elsewhere and are summarized in
Figure 1A (Binley et al., 2000; Julien et al., 2013b; Khayat et al.,
2013; Klasse et al., 2013; Lyumkis et al., 2013; Sanders et al.,
2002, 2013). We first produced BG505 SOSIP.664 trimers from
a stable HEK293T cell line as previously described (Chung
et al., 2014). We analyzed the enzymatically released and
fluorescently labeled N-glycans by hydrophilic interaction chro-
matography-ultra-performance liquid chromatography (HILIC-
UPLC) to determine the trimer’s overall glycan profile (Figure 1B).2696 Cell Reports 14, 2695–2706, March 22, 2016 ª2016 The AuthorEndoglycosidase H (Endo H) cleavage of the released glycan
pool established that 63% of the total glycans were of the oligo-
mannose type.
To probe the glycan structures in greater detail and to facilitate
the processing of subsequent site analysis data, we generated a
database of the N-glycans present. For this purpose, unlabeled
glycans released from the gp120 and gp41 subunits were
analyzed separately by ion mobility-electrospray ionization
mass spectrometry (IM-ESI MS; Figure 1C). Glycans were iden-
tified, and isomeric structures were assigned using negative ion
fragmentation mode (Harvey et al., 2011). In total, 52 and 59
isobaric structures were identified on gp120 and gp41, respec-
tively (Table S1). Consistent with the UPLC data, a significant oli-
gomannose population was present on gp120. We obtained fine
structural details of the highly processed gp41 glycans, which
were dominated by unsialylated galactose-terminating bi- and
triantennary structures (Figure 1C).
Overall, the mass spectrometry (MS) data reveal the extremes
of glycanprocessing andprotection that aredisplayed across the
surface of the densely glycosylated trimer. The site-specific vari-
ation in glycan structures arises from the intersection between
the folding of Env into its quaternary structure and how the pro-
ducer cell’s processing enzymes then see the folded trimer.
Quantitative Site-Specific Glycan Analysis
To quantify the distribution of under-processed oligomannose-
type glycans and specify the locations of the highly processed
complex-type glycans, we used a parallel mass-spectrometric-
based approach exploiting two different ionization modes.
In one strategy, we generated glycopeptides from BG505
SOSIP.664 trimers by trypsin digestion, fractionated them by
reverse-phase high-performance liquid chromatography (RP-
HPLC), and analyzed the resulting glycopeptide pools using
MALDI-TOF MS. In total, 11 glycan sites could be isolated and
quantified by assessment of the ion abundances (Figure S1; Ta-
bles S2 and S3). In an alternative approach, the total pool of
trypsin- and chymotrypsin-digested glycopeptides was ana-
lyzed by coupled, in-line liquid chromatography-ESI (LC-ESI)
MS. Here again, we determined the relative abundance of each
specific glycan structure by summing the ion intensity of the cor-
responding glycopeptide over all identified charge states. This
quantification procedure is justified, because protonation of gly-
copeptides occurs mainly on the peptide backbone; the method
has been validated previously, albeit using simpler targets
(Wada, 2013). Nevertheless, our complementary analytical ap-
proaches enabled an additional validation of the relative quanti-
fication performed here.
The glycan compositions derived by the two methods are
compared in Figure 2, which shows three representative
N-glycan sites corresponding to those dominated by oligoman-
nose structures, complex-type structures, or a mixed population
of both glycan classes. The two datasets are highly concordant,
indicating that each method reliably captures the processing
state of an isolated glycosylation site. Using the glycan database
generated by the ion mobility MS of released glycans (Figure 1),
analysis of the LC-ESI MS data allowed 20 occupied N-linked
glycosylation sites to be characterized in detail (Figure 3; Tables
S4, S5, and S6). The remaining eight sites could not bes
Figure 1. Glycosylation Pattern of BG505
SOSIP.664 Trimers
(A) Schematic representation of the BG505
SOSIP.664 construct, including PNGSs and
incorporated modifications.
(B) HILIC-UPLC profile of N-linked glycans from
BG505 SOSIP.664 trimers stably produced in
HEK293T cells and purified by 2G12-affinity
chromatography/SEC. Oligomannose-type and
hybrid glycans (green) were identified by their
sensitivity to Endo H digestion. Pink indicates
complex glycans. Rel., relative.
(C) Negative ion electrospray spectra of N-glycans
found on the gp120 (upper panel) and gp41ECTO
(middle panel) subunits of BG505 SOSIP.664 tri-
mers; and mobility-extracted singly charged
negative ions from desialylated gp41ECTO glycans
(bottom). Symbols are as explained in (B).
See also Table S1.quantified; they were present either on a peptide containing
more than one N-glycan (e.g., N133 and N137) or on a glycopep-
tide that could not be identified with sufficient confidence (e.g.,
N398 and N625). The latter scenario is likely to be attributable
to either incomplete occupancy of the N-glycosylation site or a
low ionization efficiency.
The overall percentages of oligomannose-type versus pro-
cessed glycans confirm that the glycosylation sites on the
gp120 subunits are largely dominated by oligomannose-type
structures, whereas more highly processed glycans dominate
on gp41. However, there are exceptions to these generalizations
on both subunits, which we explore later. We generated amap of
the distribution of the different processing states across the
BG505 SOSIP.664 trimer by constructing a model based on its
cryoelectron microscopy (cryo-EM) structure at a 4.36-A˚ resolu-
tion (Lee et al., 2015) (Figure 3B). The model reveals a mosaic of
sites bearing oligomannose-type glycans, complex glycans, or a
mixture of both (green, pink, and orange, respectively; Figure 3).Cell Reports 14, 2695–2706However, the distribution is not random,
and a network of oligomannose glycans
is evident across the trimer surface. The
heterogeneity of the glycan-processing
states indicates that there must be hot-
spots of accessibility to the producer
cell’s glycan-processing enzymes. In the
following text, we discuss examples of
how even closely proximal glycans can
differ substantially in their processing
states.
Clusters of Under-processed
Glycans
The trimer apex is covered by a ring of six
glycans created by two individual sites
(N156 and N160) from the V1/V2 regions
of each of the three protomers. All six gly-
cans in this ring are minimally processed,
which we attribute to inter-glycan interac-tions among these topologically proximal structures that shield
each of them from the processing enzymes. Man9GlcNAc2 moi-
eties dominate at the N156 position, whereas the N160 glycan is
slightly more processed, although still predominantly of the
oligomannose type (Figure 3). Glycans N234 and N276 near the
CD4-binding site (CD4bs) also behave as a linked, minimally pro-
cessed pair on each individual gp120 protomer, and we note that
they are separated at the Asn Ca positions by only 10.6 A˚ (PDB:
5ACO) (Lee et al., 2015). This degree of proximity may again
be sufficient for bidirectional protection from enzymatic process-
ing, albeit with one partner again being slightlymore shielded than
the other. Thus, here, N276 is partially oligomannose-trimmed
towardMan5GlcNAc2,with somehybrid andsmall complex struc-
turesalsopresent,whereasN234 iseven lessprocessed. Theway
in which glycans proximal to the CD4bs are processed has been
proposed to influence how antibodies interact with this critical re-
gion of Env (Kong et al., 2010). In this general context, it is relevant
that Fab fragments of several CD4bs-targeting antibodies bind, March 22, 2016 ª2016 The Authors 2697
Figure 2. Comparison of Glycan Abundances Determined by
MALDI-TOF MS and LC-ESI MS
(A–C) Side-by-side bar graph representation of the relative glycan abundances
determined by MALDI-TOF MS and LC-ESI MS for three representative sites
identified by trypsin digests. Shown are examples of N-glycosylation sites
dominated by (A) complex-type glycans (pink; N88), (B) oligomannose glycans
(green; N339), or (C) a mixture of structures (N355). Repeats of the LC-MS ESI
analysis were performed, and the SEM is indicated on the bar graphs. Fig-
ure S1 shows the quantification of the remaining glycosylation sites isolated
and analyzed byMALDI-TOFMS. Glycans were grouped as shown in Table S2
and quantified by summing up ion intensities. Briefly, the grouping is based on
the number of residues within the oligomannose series (M) or the number of
antennae (A) with and without core fucose (F) in a complex glycan.
See also Tables S3, S4, and S5.markedly faster, but also with higher off-rate constants, to BG505
SOSIP.664 trimer mutants lacking the N276 glycan that abuts the
CD4bs (Figure S2). A further example of how the dense clustering
of glycansmay sterically impede the accessof glycan-processing
enzymes to their substrates involves the mannose patch on the
gp120 outer domain (Figure 3B).
Fine Structure of the Mannose Patch
Two densely packed microclusters are centered on residues
N295 and N392 that, together, form a large patch of predomi-2698 Cell Reports 14, 2695–2706, March 22, 2016 ª2016 The Authornantly Man9GlcNAc2 glycans (Figure 3B). Here, the N295
glycan is intimately embraced by its counterparts at positions
N262, N448, N332, and N301. We were unable to characterize
the N301 glycan in this analysis, but oligomannose-type gly-
cans have previously been identified at this position (Guttman
et al., 2014). The N392, N363, and N386 glycans form a closely
packed microcluster, with their Ca atoms as close together as
7.1 A˚ (N363 to N392), 8.8 A˚ (N363 to N386), and 11.5 A˚ (N386 to
N392) (PDB: 5ACO) (Lee et al., 2015). This roughly triangular
array of glycans is further surrounded by those on N137,
N197, N133, and N339. The N332 glycan, a key component
of the so-called ‘‘supersite’’ of immune vulnerability (Kong
et al., 2013; Mouquet et al., 2012; Pejchal et al., 2011; Walker
et al., 2011), resides at the heart of this site. Its location be-
tween the two component microclusters links them into a single
large oligomannose patch that stretches around the entire
gp120 outer domain. The N332 glycan itself is in close contact
with, or in close proximity to, N295, N301, and N137. Overall,
the mannose patch is stabilized by the now-revealed glycan-
glycan interactions within and/or between the two individual
microclusters.
Interprotomer Control of Glycan Processing
In addition to glycan clustering effects, we also found regions of
the trimer where interprotomer interactions and the resulting
steric effects are likely to limit glycan processing. For example,
N197 bears a mix of oligomannose-type and complex N-gly-
cans and resides very close to the V3 region of gp120 from
the adjacent protomer (Figure 3B). As such interactions could
only occur in the context of a properly assembled trimer, our
observation is not inconsistent with reports that the N197
glycan of monomeric gp120 proteins contains complex glycans
(Go et al., 2013; Leonard et al., 1990; Pritchard et al., 2015b).
The same general scenario applies to the N156, N160, and
N276 glycans that are complex when in the context of mono-
meric gp120 (Go et al., 2013; Leonard et al., 1990; Zhu et al.,
2000). We now show that each of these glycans is predomi-
nantly of the oligomannose type when present on the BG505
SOSIP.664 trimer. Hence, all of these sites are subject to the
additional constraints imposed on processing enzymes by the
interprotomer interactions that apply at the trimer level but
that are irrelevant to gp120 monomers (Pritchard et al.,
2015d). Overall, our analyses reveal key molecular features of
the TAMP (Crispin and Doores, 2015).
Processing of the Exposed Glycans of the Trimer Base
Complex glycans dominate the N and C termini of the BG505
SOSIP.664 trimer, which are located very close to one another
at the structure’s base (Figure 3). In particular, the highly pro-
cessed gp120 N88 glycan is located immediately proximal to
the gp41 subunit. Of the three glycan sites identified on
gp41, N611 and N618 display a broad range of complex
glycans (Figure 3; Tables S4 and S5), whereas N637 is less
extensively processed; a significant proportion of these struc-
tures are in oligomannose-type form. An explanation for the
mixed-processing status of the N637 glycan could be trimer-
induced steric hindrance caused by its proximity to gp120 gly-
cans N234 and N276. The comparatively limited (relative tos
Figure 3. Site-Specific Glycosylation Pro-
files of BG505 SOSIP.664 Trimers
(A) Relative quantification of 20 N-glycosylation
sites of BG505 SOSIP.664 trimers, stably pro-
duced in HEK293T cells. The trimers were di-
gested with trypsin or chymotrypsin, enriched
for glycopeptides, and analyzed by LC-ESI MS.
Glycans were grouped as shown in Table S2.
The bar graphs represent the means of two
analytical replicates; the pie charts sum-
marize the quantification of oligomannose-type
(green) and complex/hybrid glycans (pink) on
individual sites. Quantifications are based on the
peak lists in Tables S4 and S5. Percentages
corresponding to this figure can be found in
Table S6.
(B) Model of a fully glycosylated BG505
SOSIP.664 trimer. The model was constructed
using PDB: 5ACO (Lee et al., 2015), with the
following glycans modeled according to the pro-
cessing state: oligomannose-type (Man9GlcNAc2;
Woods et al., 1998), processed (galactosylated
biantennary glycan; from PDB: 1L6X), and mixed
(Man5GlcNAc2; Woods et al., 1998) sites. N301 is
classified as an oligomannose-type glycan based
on the cryo-EM structure (Lee et al., 2015) and
previously published MS analysis (Guttman et al.,
2014). Deleting the nearby glycan at residue N276
increases both the on- and off-rate constants of
the binding of CD4bs-targeting antibodies (Fig-
ure S2).
See also Figure S2 and Tables S2, S4, and S6.gp120) overall oligomannose content of the gp41 subunit that
was identified by UPLC analysis (Pritchard et al., 2015d) may,
therefore, originate from only a single site, N637. We were
only able to identify trace amounts of glycosylated peptides
corresponding to the N625 site that were insufficient to verify
by tandem MS (MS/MS). Hence, the N625 glycan site may be
markedly less occupied than the other gp41 sites. There are
previous reports of the partial or alternative occupancy of
gp41 glycan sites in general (Depetris et al., 2012; Go et al.,
2011, 2015; Pabst et al., 2012) and of the BG505 SOSIP.664 tri-
mer’s N625 glycan in particular (Guttman et al., 2014).
The BG505 SOSIP.664 trimer used for these glycan site an-
alyses is a soluble protein. It lacks not only the transmembrane
region of gp41 but also the membrane-proximal external re-
gion (MPER) (Khayat et al., 2013; Klasse et al., 2013). We
note that the highly processed N611 and N618 glycans are
each likely to be located very close to where the MPER would
be located. Thus, in the context of full-length Env, additional
shielding effects created by the MPER and the virion or cell
membrane may provide additional constraints on processingCell Reports 14, 2695–2706of the nearby N611 and N618 sites.
Even though the overall glycosy-
lation profile of a soluble SOSIP.664
trimer and a sequence-matched, mem-
brane-associated Env DCT trimer are
broadly similar (Pritchard et al., 2015d),
there may be structurally explicabledifferences in how specific sites are processed in the different
contexts.
The Mannose Patch Is Reshaped by the Presence of a
Glycan at N332
The N332 glycan at the heart of the mannose patch on the
BG505 SOSIP.664 trimer is clearly dominated by Man9GlcNAc2
moieties, as shown both by MALDI-TOF MS (Figures 4A and 4B)
and LC-ESI MS (Figures 4C and 4D). We note that the trans-
mitted/founder virus isolated from the BG505 infant 6 weeks
after birth does not contain an N-glycosylation site at position
N332 (Sanders et al., 2013; Wu et al., 2006). The SOSIP.664
trimer is based on a clone from the week-6 isolate, but with the
N332 glycan specifically introduced to create epitopes for the
multiple bNAbs that recognize it (Kong et al., 2013; Pejchal
et al., 2011; Scanlan et al., 2002; Sok et al., 2014; Walker
et al., 2011). To assess the impact of the introduced N332
glycan, we expressed and analyzed BG505 SOSIP.664 (i.e.,
N332 present) trimers and its N332A mutant in HEK293F cells
and determined their glycan profiles. Comparing the resulting, March 22, 2016 ª2016 The Authors 2699
Figure 4. Glycosylation of N332 and Its
Effect on the Glycan Shield
(A) MALDI-TOF MS spectrum of a tryptic glyco-
peptide containing N332. Observed modifications
are indicated in the box and highlighted in the
spectrum.
(B) Quantification of peak areas observed in the
MALDI-TOF spectrum.
(C) LC-ESI MS HCD fragmentation of the same
tryptic peptide (Pep) containing N332.
(D) Quantification of ion intensities for glycans
identified for N332 and analyzed by LC-ESI MS.
Error bars represent SEM.
(E) HILIC-UPLC profiles of glycans released from
BG505 SOSIP.664 transiently produced in
HEK293F cells and purified by PGT151-affinity
chromatography. Bottom spectrum: alanine-
mutated PNGS N332. Green indicates oligo-
mannose-type and hybrid glycans; pink indicates
complex glycans. Oval indicates region of spec-
trum exhibiting changes upon N332A mutation.twoHILIC-UPLCprofiles shows that the knocked-in N332 glycan
reshapes the overall glycan profile. Thus, compared to the stan-
dard trimer, the glycans released from the N332Amutant contain
fewer Man9GlcNAc2 moieties, but more Man8GlcNAc2, so that
the latter was now the most prominent N-glycan structure (Fig-
ure 4E). We interpret this observation to mean that, when the
N332 glycan is present, it influences the composition of the mul-
tiple, closely proximal glycans within the mannose patch. A likely
mechanism for this effect is steric obstruction of a-mannosidase
enzymes (Pritchard et al., 2015b). More generally, we propose
that, when the glycan shield evolves under immune selection
pressure during HIV-1 infection, there may be subtle influences
on the glycan composition of sites located some distance
away from the point at which a glycan is added or deleted.2700 Cell Reports 14, 2695–2706, March 22, 2016 ª2016 The AuthorsEffect of Glycan Site Deletions on
Neutralization Sensitivity and
Structure Integrity
To determine the impact of glycan
deletions onbNAbsensitivity,we removed
various PNGSs from the BG505.T332 (i.e.,
wild-type BG505) and the BG505.T332N
Env-pseudotyped viruses (note that the
BG505.T332N virus has the same glyco-
sylation sites as BG505 SOSIP.664 tri-
mers) (Sanders et al., 2013, 2015). Then,
we determined neutralization profiles
for a range of bNAbs to multiple epi-
topes: CD4bs (PGV04), mannose-patch
binding (PGT121, PGT128, PGT130, and
PGT135), V1/V2 loop (PG9 and PGT145),
and gp120/gp41 interface (PGT151) (Fig-
ure 5). As expected, when glycans known
to be key components of epitopes were
absent, bNAb sensitivity was substantially
reduced or lost entirely. For example,
removing the N156 or N160 glycans from
either of the BG505 test viruses reducedthe neutralization activities of PG9 and PGT145; likewise, for gly-
cans N295 or N301 with PGT128 and PGT130. However, we also
observed some unexpected outcomes. Thus, eliminating the
N197 glycan substantially reduced (BG505.T332) or entirely abla-
ted (BG505.T332N) the neutralization activity of theV1/V2-binding
bNAb PGT145. Similarly, deleting the N197 glycan from the
BG505.T332 virus also reduced its sensitivity to PG9. We note
that the N197 site contains a mixture of glycoforms (Figure 3)
and is located at the trimer apex near the protomer interface.
We propose that its removal indirectly affects the binding of
various mannose-dependent bNAbs by perturbing the glycans
at the trimer apex.
To further explore some of these phenomena, we created
several double-PNGS deletion mutant trimers on the BG505
SOSIP.664 N332A background, together with the corresponding
single mutants. The trimers were produced as described earlier,
and their glycan profiles were analyzed byHILIC-UPLC. The rela-
tive impact of single-site deletions on the abundance of oligo-
mannose-type glycans was generally significantly less than
when two sites were deleted (Figure 6; Figure S3). However, it
is notable that the overall reduction in oligomannose content
transcends what would be predicted solely from the engi-
neered loss of the individual glycans. As noted earlier, the
N332 site has a significant influence on the wider composition
of the glycan shield on BG505 SOSIP.664 trimers. This obser-
vation is reinforced by studies using mannose-patch binding
bNAbs and mutant viruses (Figure 5). Specifically, the
BG505.T332 virus (which lacks the N332 glycan) is more
affected by the deletion of additional glycans, compared to
BG505.T332N (which contains it). Thus, unexpectedly, the
glycan epitopes for PGT128 and PGT130 are particularly
strongly impaired when the N448 glycan is deleted from the
BG505.T332 virus, more so than seen with BG505.T332N.
Of note is that, in the SOSIP.664 trimer context, the double
deletion of N332 and N448 has quite a strong impact on the
overall abundance of oligomannose, as does the dual elimina-
tion of N332 and N262 (Figure 6). We noted that deleting the
N262 glycan also reduces the sensitivity of the BG505.T332
virus to neutralization by PGT128. However, the impact of
removing the N262 glycan may be explained by its critical
role in gp120 folding (Mathys et al., 2014; Moore et al., 1994)
and in influencing the conformation of the N301 glycan (Kong
et al., 2015).
Conversely, and unexpectedly, certain bNAbs to the
mannose-patch epitopes more potently neutralize BG505 virus
mutants that lack some outer domain glycans. Deleting the
N137 glycan renders both BG505 test viruses more sensitive
to PGT128 and PGT130 and makes BG505.T332N more vulner-
able to PGT121 and PGT135, but the corresponding change has
no meaningful effect on oligomannose content in the SOSIP.664
trimer context (Figure 6). The likely explanation is that the loss of
the N137 glycan increases the overall accessibility of the
mannose-patch epitopes but without affecting the average
composition of the glycan shield (Doores et al., 2015; Garces
et al., 2015).
The CD4bs antibody PGV04 more strongly neutralized the
N197 and N301 single-deletion mutants of the BG505.T332
and BG505.T332N viruses. This outcome is consistent with,
and extends, a recent report that deleting the N197 glycan
from a diverse panel of HIV-1 isolates generally increases their
sensitivity to CD4bs bNAbs, presumably via increased epitope
accessibility (Townsley et al., 2015).
Glycan-Dependent Epitope of the Trimer Apex
The PG9 epitope is critically dependent on the trimer apex gly-
cans N156 and N160 (Amin et al., 2013; Julien et al., 2013a;
Walker et al., 2009). On the BG505 SOSIP.664 trimer, the
N156 site is exclusively occupied by oligomannose-type gly-
cans, mainly Man9GlcNAc2 (Figure 3). This observation is in
marked contrast with a report that sialylated complex struc-
tures play a critical role in how PG9 recognizes the N156 glycan
(Amin et al., 2013) and also with the proposal that sialylatedCellhybrid glycans are targeted by the related PG16 antibody (Pan-
cera et al., 2013). These studies used a scaffolded V1/V2 region
of the trimer, and we suggest that, although antibodies may be
able to bind such fragments, their glycans may not be close
mimics of the native setting. A related observation is that, in
the trimer context, N160 can now be seen to be occupied by
a mixed array of glycans, in which Man8GlcNAc2 predominates.
This information supersedes the suggestion, based on simpler
structures, that processed Man5GlcNAc2 moieties play a crit-
ical role in how PG9 recognizes the N160 glycan (Amin et al.,
2013). It is unclear how the presence of kifunensine-induced
Man9GlcNAc2 moieties impedes viral neutralization by PG9
and PG16 (Doores and Burton, 2010). One explanation is that
PG9 and PG16 may simply not bind Man9GlcNAc2 structures
very well. However, an alternative hypothesis is that driving
all three N160 glycans to the larger structure (i.e., by the use
of kifunensine) distorts the packing of the trimer apex, with im-
plications for the presentation of the PG9 epitope. Overall, we
now show that the PG9 epitope, in the trimer context, is sub-
stantially more oligomannose tolerant/dependent than has
been thought. Our findings are concordant with the observation
that PG9 binds comparably to BG505 SOSIP.664 trimers
regardless of whether they are produced in HEK293T cells
(which permit glycan processing) or GnTI-deficient HEK293S
cells (which restrict glycans to oligomannose forms) (Julien
et al., 2013a).
The knowledge we present on the site-specific glycan
composition of bNAb epitopes should inform us about the
types of immunological response that Env vaccine candidates
may need to induce. As additional native-like recombinant tri-
mers become available, including ones specifically engineered
to better present epitopes for glycan-influenced bNAbs or
their germline precursors, site-specific glycan analysis will
become a critical tool that will, in turn, generate yet more infor-
mation to guide further design improvements. In the context of
HIV-1 infection, we also propose that the dense network of
glycans that covers the Env trimer will tend to promote the
presence of particular carbohydrate structures, despite the
underlying and much greater diversity at the amino-acid-
sequence level.
EXPERIMENTAL PROCEDURES
A more detailed description of the experimental procedures is provided in the
Supplemental Experimental Procedures.
Overview of BG505 Constructs
BG505 SOSIP.664 trimers used for site-specific MS analysis were stably
expressed in HEK293T cells as previously described (Chung et al., 2014).
The effects of deleting individual glycan sites were studied by making spe-
cific mutants of His-tagged BG505 SOSIP.664 trimers (Sanders et al.,
2013), which were transiently expressed in HEK293F cells. Neutralization as-
says were conducted with Env-pseudoviruses produced in HEK293T cells.
Viruses based on the full-length wild-type BG505 Env (termed here
BG505.T332), or the BG505.T332N point mutant in which the N332 glycan
site was restored, served as the basis for introducing specific mutations to
delete one or two PNGSs. Mutations were made using the QuikChange
Mutagenesis (Agilent Technologies) system according to the manufacturer’s
instructions. The primers used and the mutants created are listed in Tables
S7 and S8, respectively.Reports 14, 2695–2706, March 22, 2016 ª2016 The Authors 2701
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Figure 6. Impact of Individual Glycan Sites on Total Trimer Glyco-
sylation
The figure shows the effects of various single- and double-glycan site de-
letions on the overall abundance of oligomannose-type glycans (M5-9; green),
as well as on the individual abundance of Man9GlcNAc2 (M9; dark green). His-
tagged BG505 SOSIP.664 trimers were transiently expressed in HEK293F
cells and purified by PGT151-affinity chromatography. Bands corresponding
to the trimeric protein were excised from native gels and subjected to glycan
analysis. The abundance of oligomannose-type glycans were determined by
the integration of corresponding HILIC-UPLC peaks with or without Endo H
treatment. The y axis represents the change in percentage of oligomannose-
type glycans of a mutant relative to the non-mutated BG505 SOSIP.664 trimer
control and is calculated as follows: percent change = [(% oligomannose in
control%oligomannose in mutant)/(% oligomannose in control)]3 100. The
two dashed lines represent the decrease in oligomannose abundance that
would be predicted to arise solely by the deletion of one or twoN-glycosylation
sites that are exclusively occupied by oligomannose-type glycans when pre-
sent on the control trimer.
See also Figure S3.Expression and Purification of Env Trimers
BG505 SOSIP.664 trimers used for MS analysis of site-specific N-glycosyla-
tion were expressed in stable Flp-In HEK293T cells and purified by 2G12-affin-
ity chromatography followed by size exclusion chromatography (SEC), as
previously described (Chung et al., 2014). His-tagged BG505 SOSIP.664 tri-
mers and corresponding PNGS mutants (discussed earlier) were transiently
expressed in HEK293F cells, as described elsewhere (Sanders et al., 2013).
The trimers were then purified from cell culture supernatants by PGT151-
affinity chromatography, as described elsewhere (Pritchard et al., 2015d;
Ringe et al., 2015).
Env-Pseudovirus Production and Neutralization Assays
To produce Env-pseudoviruses capable of single-cycle replication, HEK293T
cells were cotransfected with plasmids encoding Env and an Env-deficientFigure 5. Glycan Site Modulation of Viral Neutralization by Glycan-Dep
Neutralization of wild-type BG505 (termed BG505.T332 in the main text) and B
pseudoviruses, by bNAbs PGT145, PG9, PGV04, PGT121, PGT128, PGT130, PG
above each panel (i.e., T332 or T332N). The plots show data from one experime
values derived from two duplicate wells ± SEM. The glycan-deletionmutants base
this antibody (Ab) is highly N332 dependent, and the parental virus already lac
increased or decreased neutralization sensitivity compared to the remaining pan
deletions is in Table S8.
Cellgenomic backbone. Supernatants containing Env-pseudoviruses were har-
vested 72 hr post-transfection for use in neutralization assays based on
TZM-bl target cells (Montefiori, 2005).
In-Gel Release of N-Linked Glycans
N-linked glycans were enzymatically released from trimers via in-gel digestion
with PNGase F. The released glycans were then either fluorescently labeled or
subjected to IM-ESI MS.
Glycan Analysis by HILIC-UPLC
Released glycans were fluorescently labeled with 2-aminobenzoic acid (2-AA),
as previously described (Neville et al., 2009; Pritchard et al., 2015d). Labeled
glycans were analyzed using a 2.1 mm 3 10 mm Acquity BEH glycan column
in a Waters Acquity UPLC instrument. Endo H digestions of labeled glycans
were used to measure the abundance of oligomannose-type glycans.
Tandem IM-ESI MS Analysis of Released N-Linked Glycans
The total pool of released glycans from BG505 SOSIP.664 trimers (from the
stable HEK293T cell line) was analyzed using IM-ESI MS with a Waters Synapt
G2Si mass spectrometer (Waters). These results were the basis for the crea-
tion of a glycan library that was then used for the subsequent site-specific
N-glycosylation analyses.
Proteolytic Digestion of BG505 SOSIP.664 Trimers and
Glycopeptide Enrichment
A 200- to 300-mg sample of trimer was used for in-solution proteolytic diges-
tion using trypsin or chymotrypsin (Mass Spectrometry Grade, Promega),
followed by enrichment of the digestion mixture for glycopeptides using the
ProteoExtract Glycopeptide Enrichment Kit (Merck Millipore). Glycopeptides
were then either directly analyzed by LC-ESI MS or fractionated by RP-HPLC
and subjected to MALDI-TOF MS.
RP-HPLC Fractionation and MALDI-TOF MS Analysis of
Glycopeptides
Glycopeptides were resuspended in PBS buffer and fractionated with RP-
HPLC a Jupiter C18 5-mm 250 3 4.5 mm column (300 A˚, Phenomenex) and a
Dionex U3000 LC system. Glycopeptide fractions were split in half. One half
was directly analyzed byMALDI-TOFMS, whereas the other half was deglyco-
sylated using PNGase F (New England Biolabs). MALDI-TOF MS was
performed using an Autoflex Speed MALDI-TOF(/TOF) instrument (Bruker).
MS/MSwas performed on both glycopeptides andpeptides to confirmpeptide
identity. Acquired datawere processed usingDataAnalysis 3 software (Bruker).
LC-ESI MS and MS/MS Analysis of Glycopeptides
Enriched glycopeptides were analyzed on a Q-Exactive Orbitrap mass spec-
trometer (Thermo Fisher Scientific) coupled to a Dionex Ultimate 3000 nanoLC
system. MS data were acquired with XCalibur 3.0.63 (Thermo Fisher Scientific)
using Top10 intense ions in 1.42-s duty cycle time. Glycopeptides were frag-
mented using higher energy collisional dissociation (HCD) fragmentation. Data
analysis and glycopeptide identification were performed using Byonic (Version
2.7) and Byologic software (Version 2.3; Protein Metrics).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
three figures, and eight tables and can be found with this article online at
http://dx.doi.org/10.1016/j.celrep.2016.02.058.endent bNAbs
G505.T332N Env-pseudoviruses, and a panel of glycan-deletion mutant Env-
T135, and PGT151. The presence or absence of the N332 glycan is indicated
nt that is representative of at least two. The error bars are based on the mean
d on the BG505.T332 virus were not analyzed for their sensitivity to PGT135, as
ks this glycan (Kong et al., 2013). Mutant Env-pseudoviruses with markedly
el are highlighted using the colors shown in the legends. The full list of PNGS
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